Structures by: Hu X. R.
Total: 25
Ivabradine hydrochloride hemihydrate
C27H37N2O5,Cl,0.5(H2O)
Acta Crystallographica Section C (2019) 75, 5 545-553
a=5.48740(10)Å b=43.4767(7)Å c=11.4892(2)Å
α=90° β=98.144(2)° γ=90°
Ivabradine hydrochloride tetrahydrate
C27H37N2O5,Cl,4(H2O)
Acta Crystallographica Section C (2019) 75, 5 545-553
a=8.6747(2)Å b=18.2437(5)Å c=38.6507(9)Å
α=90° β=90° γ=90°
C23H29ClFN3O4,H2O
C23H29ClFN3O4,H2O
Acta Crystallographica Section C (2018) 74, 6
a=12.3225(9)Å b=14.5183(8)Å c=13.8141(8)Å
α=90° β=98.361(2)° γ=90°
Regorafenib crystalline form I
C21H15ClF4N4O3
Acta Crystallographica Section C (2016) 72, 4 291-296
a=7.6972(4)Å b=24.3703(12)Å c=11.3580(7)Å
α=90.00° β=93.545(2)° γ=90.00°
Regorafenib monohydrate
C21H15ClF4N4O3,H2O
Acta Crystallographica Section C (2016) 72, 4 291-296
a=4.7783(2)Å b=21.9538(9)Å c=20.5581(8)Å
α=90.00° β=92.3410(10)° γ=90.00°
Febuxostat
C16H16N2O3S,C2H4O2
Acta Crystallographica Section E (2015) 71, 5 o295-o296
a=7.684(2)Å b=10.580(3)Å c=12.059(3)Å
α=84.897(5)° β=84.674(4)° γ=71.081(5)°
4-(2-Carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1<i>H</i>-indol-3-yl)butyl]piperazin-1-ium chloride methanol monosolvate
C26H28N5O2,Cl,CH4O
Acta Crystallographica Section E (2016) 72, 12 1783-1785
a=10.5572(5)Å b=11.0764(4)Å c=11.4408(5)Å
α=104.6220(10)° β=97.327(2)° γ=90.6950(10)°
Canagliflozin
2(C24H25FO5S),H2O
Acta Crystallographica Section E (2016) 72, 5 734-736
a=8.4259(4)Å b=11.4264(7)Å c=45.706(2)Å
α=90.00° β=90.00° γ=90.00°
Rivaroxaban
C19H18ClN3O5S
Acta Crystallographica Section E (2018) 74, 1 51-54
a=9.0184(6)Å b=10.9980(8)Å c=11.2386(8)Å
α=63.426(2)° β=74.414(3)° γ=78.144(2)°
Vortioxetine
C18H22N2S
Acta crystallographica. Section E, Crystallographic communications (2015) 71, Pt 8 883-885
a=7.6160(4)Å b=8.3267(5)Å c=13.9011(7)Å
α=84.999(2)° β=77.6310(10)° γ=74.347(2)°
1-{2-[(2,4-Dimethylphenyl)sulfanyl]phenyl}piperazine methanol monosolvate
C18H22N2S,CH4O
Acta crystallographica. Section E, Crystallographic communications (2015) 71, Pt 8 883-885
a=13.2100(7)Å b=18.1500(9)Å c=8.1746(4)Å
α=90.00° β=104.378(2)° γ=90.00°
1-Phenyl-2-(toluene-4-sulfonyl)ethanone
C15H14O3S
Acta Crystallographica Section E (2004) 60, 6 o1115-o1116
a=15.8077(7)Å b=5.4113(2)Å c=15.8940(9)Å
α=90° β=95.343(2)° γ=90°
C19H18BrN3O3
C19H18BrN3O3
Acta Crystallographica, Section E: Structure Reports Online (2003) 59, 9 o1393-o1394
a=8.7821(5)Å b=10.3347(6)Å c=10.9750(10)Å
α=104.779(5)° β=92.572(2)° γ=105.331(2)°
3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propionohydrazide
C17H28N2O2
Acta Crystallographica Section E (2005) 61, 12 o4190-o4191
a=6.1848(16)Å b=14.685(5)Å c=19.097(5)Å
α=90.0000° β=95.439(10)° γ=90.0000°
N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenylsulfanyl)-2-hydroxy- 2-methylpropionamide
C18H14F4N2O2S
Acta Crystallographica Section E (2006) 62, 10 o4545-o4546
a=10.136(5)Å b=10.343(6)Å c=10.524(4)Å
α=106.82(2)° β=116.97(2)° γ=95.19(2)°
Memantinium chloride 0.1-hydrate
C12H22N,Cl,0.1(H2O)
Acta Crystallographica Section E (2009) 65, 9 o2191
a=28.3787(11)Å b=28.3787(11)Å c=8.5236(4)Å
α=90.00° β=90.00° γ=120.00°
2-(Cyclohexa-1,4-dienyl)-2-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-\ dimethylethanaminium chloride
C17H24NO,Cl
Acta Crystallographica Section E (2009) 65, 8 o1916
a=11.1245(7)Å b=10.9248(6)Å c=28.9651(16)Å
α=90.0000° β=90.0000° γ=90.0000°
Triamcinolone acetonide acetate
C26H33FO7
Acta Crystallographica Section E (2011) 67, 2 o360
a=7.5460(7)Å b=14.8102(4)Å c=11.5773(3)Å
α=90.00° β=109.9050(10)° γ=90.00°
Eprosartan mesylate
C23H25N2O4S,CH3O3S
Acta Crystallographica Section E (2011) 67, 4 o770-o771
a=8.6635(4)Å b=12.6935(7)Å c=13.6679(8)Å
α=112.700(2)° β=101.3860(10)° γ=96.7180(10)°
Febuxostat methanol monosolvate
C16H16N2O3S,CH4O
Acta Crystallographica Section E (2011) 67, 5 o1232
a=4.7089(3)Å b=17.9073(13)Å c=10.7965(8)Å
α=90.00° β=98.047(2)° γ=90.00°
Quetiapine <i>N</i>-oxide--fumaric acid (2/1)
2(C21H25N3O3S),C4H4O4
Acta Crystallographica Section E (2012) 68, 6 o1753-o1754
a=13.1299(9)Å b=12.5047(8)Å c=13.9950(9)Å
α=90.00° β=101.59(2)° γ=90.00°
<i>N</i>-[1-(3-Chlorophenyl)-1-oxopropan-2-yl]-<i>tert</i>-butanaminium bromide propanol hemisolvate
C13H19ClNO,Br,0.5(C3H8O)
Acta Crystallographica Section E (2011) 67, 10 o2772
a=7.8614(4)Å b=9.4100(6)Å c=11.8477(7)Å
α=85.783(2)° β=78.159(2)° γ=89.450(2)°
7-[(1<i>S</i>,6<i>S</i>)-8-aza-2-azoniabicyclo[4.3.0]non-8-yl]-1-cyclopropyl-6- fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid chloride monohydrate
C21H25FN3O4,Cl,H2O
Acta Crystallographica Section E (2011) 67, 10 o2773-o2774
a=6.7280(3)Å b=10.6406(5)Å c=15.3127(7)Å
α=91.7293(14)° β=91.1313(13)° γ=100.8823(13)°
9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)- 7-oxo-7<i>H</i>-pyrido[1,2,3-<i>ij</i>][1,2,4]benzoxadiazine-6-carboxylic acid
C17H19FN4O4
Acta Crystallographica Section E (2012) 68, 4 o998-o999
a=8.0145(5)Å b=8.9218(6)Å c=13.0874(8)Å
α=91.65(3)° β=99.65(3)° γ=115.091(10)°
C17H19ClN2
C17H19ClN2
Zeitschrift für Kristallographie - New Crystal Structures (2003) 218, 4 497-498
a=18.0920(1)Å b=5.8896(1)Å c=14.6011(2)Å
α=90° β=90° γ=90°